Clinical Trial Update: Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod [Phase 4]

View source ↗

Summary

A Phase 4 prospective study is evaluating sequencing of anti-CD20 therapies before starting Ozanimod in Relapsing Multiple Sclerosis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Zeposia (ozanimod) (ozanimod)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: RECRUITING